Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% on Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK) shares traded down 14.1% during trading on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares traded hands during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

A number of other equities research analysts have also issued reports on HIK. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a research note on Friday. Deutsche Bank Aktiengesellschaft cut their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a report on Tuesday, August 12th. JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday. Finally, Peel Hunt reissued a “buy” rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research note on Friday. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of “Buy” and an average price target of GBX 2,416.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Mazen Darwazah acquired 315,000 shares of Hikma Pharmaceuticals stock in a transaction on Thursday, November 6th. The shares were purchased at an average cost of GBX 1,601 per share, for a total transaction of £5,043,150. Also, insider Laura Balan Balan bought 3,500 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was bought at an average cost of GBX 1,821 per share, with a total value of £63,735. Insiders bought 332,500 shares of company stock valued at $533,130,500 over the last 90 days. Insiders own 17.77% of the company’s stock.

Hikma Pharmaceuticals Price Performance

The company has a market cap of £3.50 billion, a PE ratio of 9.47, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The stock has a fifty day moving average price of GBX 1,730.88 and a 200-day moving average price of GBX 1,894.04.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.